Total Payments
$19,760
2021 Payments
$8,396
Companies
22
Transactions
202
Medicare Patients
2,100
Medicare Billing
$272,474
Payment Breakdown by Category
Other$14,523 (73.5%)
Food & Beverage$4,091 (20.7%)
Consulting$1,058 (5.4%)
Travel$49.45 (0.3%)
Education$38.56 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,523 | 10 | 73.5% |
| Food and Beverage | $4,091 | 188 | 20.7% |
| Consulting Fee | $1,058 | 1 | 5.4% |
| Travel and Lodging | $49.45 | 1 | 0.3% |
| Education | $38.56 | 2 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $15,547 | 60 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $1,966 | 48 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $492.95 | 12 | $0 (2020) |
| Actelion Pharmaceuticals US, Inc. | $369.10 | 12 | $0 (2020) |
| United Therapeutics Corporation | $327.33 | 12 | $0 (2020) |
| Genentech USA, Inc. | $215.14 | 10 | $0 (2020) |
| Mylan Specialty L.P. | $159.73 | 9 | $0 (2020) |
| Philips Electronics North America Corporation | $131.32 | 7 | $0 (2020) |
| GENZYME CORPORATION | $71.76 | 3 | $0 (2020) |
| Insmed, Inc. | $69.38 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $8,396 | 13 | GlaxoSmithKline, LLC. ($7,204) |
| 2020 | $8,448 | 63 | GlaxoSmithKline, LLC. ($7,606) |
| 2019 | $1,998 | 91 | GlaxoSmithKline, LLC. ($500.15) |
| 2018 | $723.45 | 33 | GlaxoSmithKline, LLC. ($236.60) |
| 2017 | $194.42 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($194.42) |
All Payment Transactions
202 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/13/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $4.04 | General |
| Category: RESPIRATORY | ||||||
| 07/22/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: RESPIRATORY | ||||||
| 07/17/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: Respiratory | ||||||
| 07/13/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $1,057.50 | General |
| Category: Respiratory | ||||||
| 05/06/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $73.15 | General |
| Category: Respiratory | ||||||
| 05/05/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: Respiratory | ||||||
| 04/29/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: RESPIRATORY | ||||||
| 04/22/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: RESPIRATORY | ||||||
| 03/25/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: RESPIRATORY | ||||||
| 03/16/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Respiratory | ||||||
| 02/25/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: RESPIRATORY | ||||||
| 01/28/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: RESPIRATORY | ||||||
| 01/27/2021 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological), BREZTRI | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: Respiratory | ||||||
| 12/16/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: RESPIRATORY | ||||||
| 12/01/2020 | Advanced Respiratory, Inc | Life 2000 Ventilation System (Device) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Airway Clearance Device | ||||||
| 11/30/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: RESPIRATORY | ||||||
| 11/23/2020 | AstraZeneca Pharmaceuticals LP | BREZTRI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Respiratory | ||||||
| 11/13/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: RESPIRATORY | ||||||
| 11/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $30.80 | General |
| Category: IMMUNOLOGY | ||||||
| 11/09/2020 | United Therapeutics Corporation | ORENITRAM (Drug) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: PAH | ||||||
| 11/06/2020 | Advanced Respiratory, Inc | The Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: Airway Clearance Device | ||||||
| 11/05/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: RESPIRATORY | ||||||
| 11/05/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Travel and Lodging | Cash or cash equivalent | $49.45 | General |
| Category: RESPIRATORY | ||||||
| 11/03/2020 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Immunology | ||||||
| 11/02/2020 | AstraZeneca Pharmaceuticals LP | BREZTRI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 225 | 332 | $191,379 | $50,104 |
| 2022 | 5 | 212 | 363 | $194,657 | $50,615 |
| 2021 | 13 | 707 | 883 | $217,020 | $78,164 |
| 2020 | 14 | 956 | 1,204 | $237,135 | $93,592 |
Total Patients
2,100
Total Services
2,782
Medicare Billing
$272,474
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 145 | 231 | $160,797 | $40,676 | 25.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 69 | 89 | $27,978 | $8,642 | 30.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 12 | $2,604 | $786.40 | 30.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 111 | 214 | $144,674 | $37,784 | 26.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 58 | 88 | $27,424 | $7,283 | 26.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $11,948 | $3,035 | 25.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 30 | $6,510 | $1,749 | 26.9% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2022 | 11 | 11 | $4,101 | $763.20 | 18.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 83 | 169 | $99,683 | $31,275 | 31.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 89 | 111 | $20,860 | $10,842 | 52.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 54 | 54 | $16,147 | $7,125 | 44.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 76 | 93 | $10,810 | $5,912 | 54.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 36 | 74 | $11,183 | $4,576 | 40.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 20 | $8,270 | $3,353 | 40.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 31 | 38 | $8,209 | $3,292 | 40.1% |
| 94729 | Measurement of lung diffusing capacity | Office | 2021 | 70 | 70 | $8,089 | $2,983 | 36.9% |
| 94726 | Determination of lung volumes using plethysmography | Office | 2021 | 68 | 68 | $7,754 | $2,645 | 34.1% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 71 | 71 | $13,198 | $2,269 | 17.2% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2021 | 15 | 21 | $4,857 | $1,922 | 39.6% |
| 36556 | Insertion of central venous catheter for infusion, patient 5 years or older, not tunneled | Facility | 2021 | 12 | 12 | $4,873 | $828.24 | 17.0% |
| 94618 | Test for exercise-induced lung stress | Office | 2021 | 25 | 25 | $1,731 | $655.92 | 37.9% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Facility | 2021 | 22 | 22 | $572.00 | $186.34 | 32.6% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2021 | 17 | 17 | $442.00 | $167.96 | 38.0% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2021 | 18 | 18 | $342.00 | $131.94 | 38.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 62 | 125 | $61,781 | $23,635 | 38.3% |
About Dr. Christian Lafalce, M.D
Dr. Christian Lafalce, M.D is a Pulmonary Disease healthcare provider based in Winchester, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932219730.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christian Lafalce, M.D has received a total of $19,760 in payments from pharmaceutical and medical device companies, with $8,396 received in 2021. These payments were reported across 202 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($14,523).
As a Medicare-enrolled provider, Lafalce has provided services to 2,100 Medicare beneficiaries, totaling 2,782 services with total Medicare billing of $272,474. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine, Pulmonary Disease
- Location Winchester, VA
- Active Since 08/30/2006
- Last Updated 01/05/2026
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1932219730
Products in Payments
- TRELEGY ELLIPTA (Drug) $14,929
- BREZTRI (Drug) $1,169
- NUCALA (Biological) $459.74
- FASENRA (Drug) $376.53
- SYMBICORT (Drug) $334.61
- OFEV (Drug) $186.19
- UPTRAVI (Drug) $153.96
- Esbriet (Biological) $143.69
- ORENITRAM (Drug) $132.61
- Yupelri (Drug) $126.97
- OPSUMIT (Drug) $125.38
- NONE (Drug) $123.44
- inCourage (Device) $102.20
- SPIRIVA RESPIMAT (Drug) $95.95
- DUPIXENT (Biological) $92.35
- OPSUMIT MACITENTAN (Drug) $89.76
- Xolair (Biological) $71.45
- GLASSIA (Biological) $71.44
- ANORO (Drug) $70.64
- Arikayce (Drug) $69.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Winchester
T. Bouder, Md, MD
Pulmonary Disease — Payments: $143,021
Pulmonary Disease $143,021
Santa Dalessio, Md, MD
Pulmonary Disease — Payments: $51,548
Pulmonary Disease $51,548
Dr. Oscar Hernandez-Cano, M.d, M.D
Pulmonary Disease — Payments: $4,815
Pulmonary Disease $4,815
Thomas Murphy, Md, MD
Pulmonary Disease — Payments: $2,789
Pulmonary Disease $2,789
Gordon Wolfe, Md, MD
Pulmonary Disease — Payments: $895.05
Pulmonary Disease $895.05
Dr. David Lecronier, D.o, D.O
Pulmonary Disease — Payments: $540.82
Pulmonary Disease $540.82